Two-Year Analysis of CARTITUDE-1 Shows Early, Durable and Deepening Responses of Ciltacabtagene Autoleucel (cilta-cel) in Heavily Pretreated Patients with Multiple Myeloma
Go back to Two-Year Analysis of CARTITUDE-1 Shows Early, Durable and Deepening Responses of Ciltacabtagene Autoleucel (cilta-cel) in Heavily Pretreated Patients with Multiple Myeloma| (NASDAQ: LEGN) | Delayed: 20.75 +1.47 (7.62%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $19.28 | 52 Week High | $ | |||
| Open | $20.02 | 52 Week Low | $ | |||
| Day High | $20.86 | P/E | N/A | |||
| Day Low | $19.84 | EPS | $ | |||
| Volume | 2,611,004 | |||||
